| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,730 | 0,790 | 02.04. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Arecor Therapeutics - Notice of FY25 Results | - | RNS | ||
| 26.03. | Arecor erhält Meilensteinzahlung von 0,5 Mio. US-Dollar aus Vereinbarung mit Ligand | 1 | Investing.com Deutsch | ||
| 26.03. | Arecor receives $0.5m milestone from Ligand deal | 1 | Investing.com | ||
| 26.03. | Arecor Therapeutics - Ligand Pharmaceuticals Milestone Payment | - | RNS | ||
| 09.03. | Arecor Therapeutics - Arecor to present at Oppenheimer conference | - | RNS | ||
| 09.02. | Arecor Therapeutics revenue falls after Tetris Pharma operations cease | 1 | Alliance News | ||
| 09.02. | Arecor's ultra-concentrated insulin advances with Sequel partnership | 2 | Investing.com | ||
| 09.02. | Arecor treibt ultrakonzentriertes Insulin durch Partnerschaft mit Sequel voran | 1 | Investing.com Deutsch | ||
| ARECOR THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.02. | Arecor Therapeutics - 2025 Business Update | - | RNS | ||
| 06.01. | Arecor Therapeutics - Fireside Panel Discussion on Diabetes sector | - | RNS | ||
| 09.12.25 | Arecor, Sequel Med Tech to host virtual panel on diabetes care | 2 | Investing.com | ||
| 09.12.25 | Arecor Therapeutics - Arecor and Sequel Med Tech to host fireside panel | - | RNS | ||
| 04.11.25 | Arecor Therapeutics - Enhanced IP Coverage: AT278 & Oral Peptide Program | - | RNS | ||
| 25.09.25 | Arecor Therapeutics PLC: Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292 | 164 | GlobeNewswire (Europe) | This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc("Arecor" or the "Company")... ► Artikel lesen | |
| 19.05.25 | Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab | 502 | GlobeNewswire (Europe) | SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|